Drug intelligence / Profile preview

HS-601

Development stage: Preclinical
Lead developer: HaplnScience
Modality: Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

HS-601 is a preclinical-stage protein biologic developed by HaplnScience for the treatment of Dry Eye Disease (DED). It is an endogenous protein-based therapeutic derived from Hyaluronan and Proteoglycan Link Protein 1 (HAPLN1), a critical component of the extracellular matrix (ECM). The mechanism of action involves modulating the ocular ECM, influencing hyaluronic acid biology, and regulating inflammatory mediators to restore ocular surface homeostasis and treat the underlying pathology of DED.

Targets

CD44 (CD44 antigen)FMOD (Fibromodulin / FMOD)

Beyond the preview

Go deeper on HS-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-601.

Explore the full profile